Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine

Manuela Giachelia; Francesco D'Alò; Emiliano Fabiani; Nathalie Saulnier; Annalisa Di Ruscio; Francesco Guidi; Stefan Hohaus; Maria Teresa Voso; Giuseppe Leone

doi:10.1016/j.leukres.2010.07.022

Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine

Manuela Giachelia
, Francesco D'Alò
, Emiliano Fabiani
, Nathalie Saulnier
, Annalisa Di Ruscio
, Francesco Guidi
, Stefan Hohaus
, Maria Teresa Voso
, Giuseppe Leone

Research output: Contribution to journal › Article › peer-review

Abstract

Abnormal gene promoter methylation contributes to deregulate gene expression of hematopoietic progenitors in myelodysplastic syndromes (MDS). We analyzed the gene expression profile of myelodysplastic and normal CD34+ hematopoietic stem cells (HSCs) treated in vitro with decitabine. We identified a list of candidate tumor suppressor genes, expressed at low levels in MDS HSCs and induced by hypomethylating treatment only in MDS, but not in normal HSCs. Real-time RT-PCR confirmed reduced CD9 expression in MDS CD34+ and bone marrow mononuclear cells, compared to normal controls. CD9 was specifically up-regulated by decitabine treatment in myelodysplastic CD34+ cells.

Original language	English
Pages (from-to)	465-471
Number of pages	7
Journal	Leukemia Research
Volume	35
Issue number	4
DOIs	https://doi.org/10.1016/j.leukres.2010.07.022
Publication status	Published - Apr 2011
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CD9
Gene expression profiling
Hematopoietic stem cell
Hypomethylating agents
Myelodysplastic syndromes

Access to Document

10.1016/j.leukres.2010.07.022

Cite this

@article{8c3936e7bfaa4b88bb43326424a4b8e4,

title = "Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine",

abstract = "Abnormal gene promoter methylation contributes to deregulate gene expression of hematopoietic progenitors in myelodysplastic syndromes (MDS). We analyzed the gene expression profile of myelodysplastic and normal CD34+ hematopoietic stem cells (HSCs) treated in vitro with decitabine. We identified a list of candidate tumor suppressor genes, expressed at low levels in MDS HSCs and induced by hypomethylating treatment only in MDS, but not in normal HSCs. Real-time RT-PCR confirmed reduced CD9 expression in MDS CD34+ and bone marrow mononuclear cells, compared to normal controls. CD9 was specifically up-regulated by decitabine treatment in myelodysplastic CD34+ cells.",

keywords = "CD9, Gene expression profiling, Hematopoietic stem cell, Hypomethylating agents, Myelodysplastic syndromes",

author = "Manuela Giachelia and Francesco D'Al{\`o} and Emiliano Fabiani and Nathalie Saulnier and \{Di Ruscio\}, Annalisa and Francesco Guidi and Stefan Hohaus and Voso, \{Maria Teresa\} and Giuseppe Leone",

note = "Funding Information: Authors would like to thank Dr. Pierluigi Puggioni for flow cytometry analysis and all physicians from the Department of Hematology of Universit{\`a} Cattolica del Sacro Cuore in Rome, for their indirect contribution to this work. This work was supported by Fondazione Roma “Progetto cellule staminali, Una nuova frontiera nella ricerca biomedica”. This sponsor had no involvement in the study design, in the collection, analysis and interpretation of data, in the writing of the manuscript, and in the decision to submit the manuscript for publication. ",

year = "2011",

month = apr,

doi = "10.1016/j.leukres.2010.07.022",

language = "English",

volume = "35",

pages = "465--471",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "4",

}

TY - JOUR

T1 - Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine

AU - Giachelia, Manuela

AU - D'Alò, Francesco

AU - Fabiani, Emiliano

AU - Saulnier, Nathalie

AU - Di Ruscio, Annalisa

AU - Guidi, Francesco

AU - Hohaus, Stefan

AU - Voso, Maria Teresa

AU - Leone, Giuseppe

N1 - Funding Information: Authors would like to thank Dr. Pierluigi Puggioni for flow cytometry analysis and all physicians from the Department of Hematology of Università Cattolica del Sacro Cuore in Rome, for their indirect contribution to this work. This work was supported by Fondazione Roma “Progetto cellule staminali, Una nuova frontiera nella ricerca biomedica”. This sponsor had no involvement in the study design, in the collection, analysis and interpretation of data, in the writing of the manuscript, and in the decision to submit the manuscript for publication.

PY - 2011/4

Y1 - 2011/4

N2 - Abnormal gene promoter methylation contributes to deregulate gene expression of hematopoietic progenitors in myelodysplastic syndromes (MDS). We analyzed the gene expression profile of myelodysplastic and normal CD34+ hematopoietic stem cells (HSCs) treated in vitro with decitabine. We identified a list of candidate tumor suppressor genes, expressed at low levels in MDS HSCs and induced by hypomethylating treatment only in MDS, but not in normal HSCs. Real-time RT-PCR confirmed reduced CD9 expression in MDS CD34+ and bone marrow mononuclear cells, compared to normal controls. CD9 was specifically up-regulated by decitabine treatment in myelodysplastic CD34+ cells.

AB - Abnormal gene promoter methylation contributes to deregulate gene expression of hematopoietic progenitors in myelodysplastic syndromes (MDS). We analyzed the gene expression profile of myelodysplastic and normal CD34+ hematopoietic stem cells (HSCs) treated in vitro with decitabine. We identified a list of candidate tumor suppressor genes, expressed at low levels in MDS HSCs and induced by hypomethylating treatment only in MDS, but not in normal HSCs. Real-time RT-PCR confirmed reduced CD9 expression in MDS CD34+ and bone marrow mononuclear cells, compared to normal controls. CD9 was specifically up-regulated by decitabine treatment in myelodysplastic CD34+ cells.

KW - CD9

KW - Gene expression profiling

KW - Hematopoietic stem cell

KW - Hypomethylating agents

KW - Myelodysplastic syndromes

UR - https://www.scopus.com/pages/publications/79952359985

U2 - 10.1016/j.leukres.2010.07.022

DO - 10.1016/j.leukres.2010.07.022

M3 - Article

SN - 0145-2126

VL - 35

SP - 465

EP - 471

JO - Leukemia Research

JF - Leukemia Research

IS - 4

ER -

Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this